← Leaderboards
Jason Keith Sicklick
University Of California, San Diego
$6,608,057
Attributed
$7,639,599
Total exposure
7
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.6M · FY2014–25$2M$1.5M$1M$500K$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,139,600 · 6
FDA$1,499,999 · 1
By mechanism
R01$4,290,027 · 3
U01$1,187,407 · 1
K08$887,760 · 1
T32$875,678 · 1
R21$398,727 · 1
Top collaborators
- Yuan Chen3 shared
- John Walter Glod2 shared
Most similar at University Of California, San Diego
Same institution · by research overlap
- Yin Chun Lin$154,278
- John Walter Glod$593,704
Others in their field
Top investigators on “Gastrointestinal Stromal Tumors”
- Timothy Cragin Wang · Columbia University Health Sciences$11,814,748
- Michael A Hollingsworth · University Of Nebraska Medical Center$9,488,383
- Ronald P Dematteo · Sloan-Kettering Institute For Cancer Res$9,487,240
- Cristina R Antonescu · Sloan-Kettering Inst Can Research$8,028,963
- Peter Besmer · Sloan-Kettering Institute For Cancer Res$7,103,009
- Scott Michael Schuetze · University Of Michigan At Ann Arbor$6,158,546
Research focus
Gastrointestinal Stromal TumorsTumorPathway InteractionsSarcomaImatinibMutationIn VitroNeoplastic CellBraf GeneGenesReportingMouse ModelCellsIn VivoMolecularResistanceTumor Cell LineMutantKit GeneDrug ResistanceCohortRecurrenceBaseMalignant Neoplasms
Grant awards (21)
Prognostic and Therapeutic Roles of Voltage Gated Potassium Channels in Managing KIT Mutant Gastrointestinal Stromal Tumors (GIST)$662,682
R01 · FY2025 · CA · contact PI
National Succinate Dehydrogenase-deficient GIST Translational Research and Clinical Trial Consortium$637,789
U01 · FY2025 · CA · contact PI
Surgical Oncologists as Scientists (SOAS) Training Program$336,735
T32 · FY2025 · CA · contact PI
National Succinate Dehydrogenase-deficient GIST Translational Research and Clinical Trial Consortium$549,618
U01 · FY2024 · CA · contact PI
Surgical Oncologists as Scientists (SOAS) Training Program$368,648
T32 · FY2024 · CA · contact PI
Targeting Drug-Resistant Cancer Stem Cell Niches of Gastrointestinal Stromal Tumor$421,474
R01 · FY2023 · CA · contact PI
Surgical Oncologists as Scientists (SOAS) Training Program$170,295
T32 · FY2023 · CA · contact PI
Targeting Drug-Resistant Cancer Stem Cell Niches of Gastrointestinal Stromal Tumor$426,357
R01 · FY2022 · CA · contact PI
Investigation of DNA Damaging Agents in GIST with Metabolic Dysfunction$499,999
R01 · FY2021 · FD · contact PI
Targeting Drug-Resistant Cancer Stem Cell Niches of Gastrointestinal Stromal Tumor$429,146
R01 · FY2021 · CA · contact PI
Investigation of DNA Damaging Agents in GIST with Metabolic Dysfunction$500,000
R01 · FY2020 · FD · contact PI
Targeting Drug-Resistant Cancer Stem Cell Niches of Gastrointestinal Stromal Tumor$423,106
R01 · FY2020 · CA · contact PI
Investigation of DNA Damaging Agents in GIST with Metabolic Dysfunction$500,000
R01 · FY2019 · FD · contact PI
Targeting Drug-Resistant Cancer Stem Cell Niches of Gastrointestinal Stromal Tumor$427,263
R01 · FY2019 · CA · contact PI
Novel Allosteric Kinase Inhibitors Target Imatinib-Resistant GIST$177,552
K08 · FY2018 · CA · contact PI
Defining the Germline Genomic Landscape of a Novel GIST Multi-tumor Syndrome$214,268
R21 · FY2017 · CA · contact PI
Novel Allosteric Kinase Inhibitors Target Imatinib-Resistant GIST$177,552
K08 · FY2017 · CA · contact PI
Defining the Germline Genomic Landscape of a Novel GIST Multi-tumor Syndrome$184,459
R21 · FY2016 · CA · contact PI
Novel Allosteric Kinase Inhibitors Target Imatinib-Resistant GIST$177,552
K08 · FY2016 · CA · contact PI
Novel Allosteric Kinase Inhibitors Target Imatinib-Resistant GIST$177,552
K08 · FY2015 · CA · contact PI
Novel Allosteric Kinase Inhibitors Target Imatinib-Resistant GIST$177,552
K08 · FY2014 · CA · contact PI